Amgen Hires Independent Academic Group to Recheck Data for Rare Disease Drug Under FDA Scrutiny
2026-06-11 21:16:56
Amgen Inc. engaged an independent academic organization to reevaluate data for a rare disease drug that US regulators are seeking to withdraw from the market. According to Bloomberg, the review is aimed at reassessing the drug’s data as the company faces efforts by US regulators to pull it.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
安进委托独立学术机构复核罕见病药数据
